Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quantitative Testing of Patient and Healthcare Provider Knowledge, Attitudes, and Behavior About NATPARA (Parathyroid Hormone) for Injection, for Subcutaneous Use

Next Previous
Trial Profile

Quantitative Testing of Patient and Healthcare Provider Knowledge, Attitudes, and Behavior About NATPARA (Parathyroid Hormone) for Injection, for Subcutaneous Use

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Parathyroid hormone (Primary)
  • Indications Hypoparathyroidism
  • Focus Therapeutic Use
  • Acronyms NATPARA KAB
  • Sponsors Shire

Most Recent Events

  • 08 Jan 2025 Planned End Date changed from 31 Dec 2024 to 31 Jan 2026.
  • 08 Jan 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Jan 2026.
  • 16 Nov 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top